MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SkyePharma PLC Company Profile (LON:SKP)

Consensus Ratings for SkyePharma PLC (LON:SKP) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 410.67

Analysts' Ratings History for SkyePharma PLC (LON:SKP)
Show:
DateFirmActionRatingPrice TargetActions
2/17/2016Stifel NicolausReiterated RatingBuyGBX 460View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016N+1 SingerReiterated RatingCorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016FinnCapReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/23/2015RX SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2015Oriel Securities LtdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for SkyePharma PLC (LON:SKP)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for SkyePharma PLC (LON:SKP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for SkyePharma PLC (LON:SKP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for SkyePharma PLC (LON:SKP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/29/2016Derodra,AndrewInsiderBuy32GBX 473£151.36Tweet This Trade  Share This Trade on StockTwits
3/31/2016Derodra,AndrewInsiderBuy33GBX 449£148.17Tweet This Trade  Share This Trade on StockTwits
1/2/2016Grant,PeterInsiderBuy46GBX 327£150.42Tweet This Trade  Share This Trade on StockTwits
11/30/2015Derodra,AndrewInsiderBuy46GBX 327£150.42Tweet This Trade  Share This Trade on StockTwits
11/4/2015Grant,PeterInsiderBuy47GBX 322£151.34Tweet This Trade  Share This Trade on StockTwits
10/30/2015Derodra,AndrewInsiderBuy47GBX 322£151.34Tweet This Trade  Share This Trade on StockTwits
10/5/2015Grant,PeterInsiderBuy42GBX 354£148.68Tweet This Trade  Share This Trade on StockTwits
9/4/2015Derodra,AndrewInsiderBuy48GBX 312£149.76Tweet This Trade  Share This Trade on StockTwits
8/4/2015Grant,PeterInsiderBuy54GBX 279£150.66Tweet This Trade  Share This Trade on StockTwits
7/3/2015Derodra,AndrewInsiderBuy55GBX 273£150.15Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for SkyePharma PLC (LON:SKP)
DateHeadline
07/01/16 06:25 PMVectura : Lyon manufacturing facility returns to the Vectura Group
06/30/16 06:41 PMSkyepharma (LON:SKP) Broker Roundup - Fiscal Standard
06/11/16 06:37 PMHBM Healthcare Investments : Recommended all share merger of Skyepharma and Vectura becomes effective
06/10/16 12:29 PMNotification of Major Intrest in Shares - [at noodls] - Notification of Major Intrest in Shares The text version of this document is not available at the moment. The original content was posted at original link . Vectura Group plc published this content on ...
06/10/16 10:39 AMRecommended all share merger of Skyepharma and Vectura becomes effective - [at noodls] - dedb0aee-fe09-4461-8a15-fe11258abd22.pdf Media Release Zug, 10 June 2016 Vectura Group plc (LSE: VEC) and Skyepharma plc (LSE: SKP), the largest investment in the portfolio of HBM Healthcare Investments, ...
06/10/16 07:29 AMCompany Act 2006 S430 (2B) Disclosure - [at noodls] - June 10, 2016 at 1:23 PM Further to the announcements on 16 March 2016 and 8 April 2016, Andrew Oakley stepped down as Chief Financial Officer of Vectura Group plc (the 'Company') with effect from 10 June ...
06/08/16 07:08 AMForm 8.5 (EPT/RI) - Skyepharma PLC Amendment - [at noodls] - RNS Number : 6215A JPMorgan Securities Plc 08 June 2016 AMENDMENT INCREASED EQUITY PURCHASES BY 1,435 TO 74,902 INCREASED EQUITY SALES BY 97,874 TO 127,074 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY ...
06/07/16 09:38 AMTechnology License Agreement - [at noodls] - Skyepharma signs exclusive agreement to access Lucideon's abuse deterrent drug delivery technology First product to be developed for the growing U.S.$11bnU.S. opioid market LONDON, UK, 7 June, 2016 - Skyepharma ...
06/02/16 06:55 PMSkyepharma (LON:SKP) Morning Trade Volumes - Share Trading News - Share Trading NewsSkyepharma (LON:SKP) Morning Trade VolumesShare Trading NewsSkyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company's products pipeline includes four inhalation products, 10 oral ...
06/02/16 09:33 AM'I'm looking for stocks that will double in three years - and here's what I'm backing' - Yahoo Finance UK - 'I'm looking for stocks that will double in three years - and here's what I'm backing'Yahoo Finance UKThat may be happening but actually our strong performance this year has come from some of our holdings becoming takeover targets. For example, Skyepharma (LSE: SKP.L - news) , which is being bought by Vectura, is a big holding. The recovery part of the ...and more »
06/02/16 07:25 AM'I'm looking for stocks that will double in three years - and here's what I'm backing' -
06/01/16 09:43 AMForm 8.3 - Skypepharma PLC - [at noodls] - FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) ...
05/31/16 06:47 PMVectura all set for SkyePharma merger - Investors Chronicle - Vectura all set for SkyePharma mergerInvestors Chronicle(GSK) led to a 56 per cent increased in royalty payments in the period. This is likely to be enhanced in the 2017 financial year thanks to the upcoming launch of two new Novartis drugs that use Vectura technology. Approval of these products earned the ...
04/09/16 01:48 PMAnalyst Coverage Updates - Skyepharma (LON:SKP) - Risers & Fallers - Share Trading NewsAnalyst Coverage Updates - Skyepharma (LON:SKP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Skyepharma (LON:SKP). The latest broker reports which are ... Skyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the ...Skyepharma (LON:SKP) Morning Trade VolumesShare Trading Newsall 2 news articles »
04/07/16 11:29 AMSkyePharma Plc :SKP-GB: Earnings Analysis: For the six months ended December 31, 2015 -
04/06/16 09:00 AMForm 8.3 - Skyepharma Plc -
03/17/16 06:55 AMVectura receives support from Skyepharma shareholder -
03/16/16 08:47 AMSkyepharma and Vectura agree merger; Skyepharma swings to profit -
03/16/16 07:57 AMIs Fast-Growing Skyepharma PLC Better than Vodafone Group plc? -
03/16/16 07:26 AMVectura to buy SkyePharma for $620 mln as UK biotech consolidates - [Reuters - UK Focus] - Respiratory drug specialist Vectura has agreed to buy rival SkyePharma for 441 million pounds ($621 million), in a notable piece of consolidation among Britain's universe of small biotech companies. Unlike large, successful biotechnology firms in the United States, British firms have yet to achieve critical mass and, as a result, have often struggled to secure an active following from investors and analysts. "I would expect to see a number of new holders coming into this stock, given our mid-cap market capitalisation with the combination," said James Ward-Lilley, Vectura's chief executive, who will become CEO of the enlarged group.
03/11/16 03:08 PMSkyePharma Plc : Neutral outlook but great fundamentals -
03/07/16 03:36 AMSkyePharma Plc breached its 50 day moving average in a Bearish Manner : SKP-GB : March 7, 2016 -
02/28/16 01:30 PMAre Analysts Bearish SkyePharma PLC (LON:SKP) After Last Week? - RiversideGazette.com - Are Analysts Bearish SkyePharma PLC (LON:SKP) After Last Week?RiversideGazette.comOut of 1 analysts covering SkyePharma PLC (LON:SKP), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. SkyePharma PLC was the topic in 22 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
02/26/16 08:44 AMSkyepharma (LON:SKP) Recent Analyst Updates - Risers & Fallers - Skyepharma (LON:SKP) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Skyepharma (LON:SKP). According to the latest broker reports ... Skyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the ...
02/26/16 03:33 AMSkyePharma Plc breached its 50 day moving average in a Bullish Manner : SKP-GB : February 26, 2016 -
02/23/16 01:59 PMShould You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC? - Yahoo Finance UK - Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?Yahoo Finance UKSimilarly, drug delivery specialist SkyePharma (LSE: SKP) is due to post a rise in its bottom line of 51% in 2016. When combined with its P/E ratio of 25.6, this equates to a PEG ratio of only 0.5 and indicates that there's considerable upside ...and more »
02/22/16 01:55 PMShould You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC? - AOL Money UK - Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?AOL Money UKSimilarly, drug delivery specialist SkyePharma(LSE: SKP) is due to post a rise in its bottom line of 51% in 2016. When combined with its P/E ratio of 25.6, this equates to a PEG ratio of only 0.5 and indicates that there's considerable upside potential ...and more »
02/22/16 01:55 PMAre Analysts Bullish SkyePharma PLC (LON:SKP) After Last Week? - RiversideGazette.com - Are Analysts Bullish SkyePharma PLC (LON:SKP) After Last Week?RiversideGazette.comOut of 1 analysts covering SkyePharma PLC (LON:SKP), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. SkyePharma PLC was the topic in 22 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
02/19/16 01:34 PMSkyePharma PLC (LON:SKP) Buy Rating Reconfirmed by Analysts at Stifel; The Price Objective is Set to GBX 460.00 - OctaFinance.com - SkyePharma PLC (LON:SKP) Buy Rating Reconfirmed by Analysts at Stifel; The Price Objective is Set to GBX 460.00OctaFinance.comIn a research report shared with investors and clients on today, Stifel restate their Buy rating on SkyePharma PLC (LON:SKP)'s stock. The target price per share suggests a potential upside of 25.43 % from firm's last stock price. LON:SKP is at the ...and more »
02/18/16 01:16 PMSkyePharma PLC (LON:SKP) Receives Buy Rating From Stifel Analysts - Risers & Fallers - Risers & FallersSkyePharma PLC (LON:SKP) Receives Buy Rating From Stifel AnalystsRisers & FallersSkyePharma PLC (LON:SKP) had its stock rating reiterated as 'Buy' in a report released by analysts at Stifel. Stifel today set a target price of 460 on the company's stock. According to the analyst this now indicates there is a potential increase of 24 ...SkyePharma PLC's (SKP) Buy Rating Reaffirmed at Stifel NicolausIntercooler FinancialStifel Reaffirms GBX 460.00 PT On SkyePharma PLC (LON:SKP), Reaffirms “Buy” RatingWallStreet.orgall 4 news articles »
02/16/16 06:07 AMFull Year 2015 SkyePharma PLC Earnings Release - Time Not Supplied -
02/11/16 12:32 PMRecent Broker Updates On Skyepharma (LON:SKP) - Risers & Fallers - Recent Broker Updates On Skyepharma (LON:SKP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Skyepharma (LON:SKP). The latest broker reports which are ... Skyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the ...
02/10/16 12:38 PMWhat Will Happen to SkyePharma PLC Next? The Stock Just Increased A Lot - Sonoran Weekly Review - What Will Happen to SkyePharma PLC Next? The Stock Just Increased A LotSonoran Weekly ReviewThe stock of SkyePharma PLC (LON:SKP) is a huge mover today! The stock increased 2.38% or GBX 8.25 on February 9, hitting GBX 355. About 312,653 shares traded hands or 120.17% up from the average. SkyePharma PLC (LON:SKP) has risen 26.45% ...and more »
02/09/16 12:04 PMCould SkyePharma PLC Crash Even More? The Stock Had Another Big Decline Today - Sonoran Weekly Review - Could SkyePharma PLC Crash Even More? The Stock Had Another Big Decline TodaySonoran Weekly ReviewThe stock of SkyePharma PLC (LON:SKP) is a huge mover today! The stock is up 2.99% or GBX 10.38 after the news, hitting GBX 357.12 per share. About 128,789 shares traded hands. SkyePharma PLC (LON:SKP) has risen 23.62% since July 8, 2015 and is ...and more »
02/09/16 03:35 AMSkyePharma Plc breached its 50 day moving average in a Bearish Manner : February 9, 2016 -
02/05/16 11:46 AMChart: Breath of life for respiratory market - Investors Chronicle (blog) - Investors Chronicle (blog)Chart: Breath of life for respiratory marketInvestors Chronicle (blog)Whilst GSK's share price hasn't reflected the success of new drug sales lately, looking at the trajectory of shares in companies like Skyepharma (SKP) and Vectura (VEC) - both of which license the development and distribution of respiratory products ...
02/04/16 11:36 AMHow Many SkyePharma PLC (LON:SKP)'s Analysts Are Bullish? - WallStreet.org - How Many SkyePharma PLC (LON:SKP)'s Analysts Are Bullish?WallStreet.orgOut of 1 analysts covering SkyePharma PLC (LON:SKP), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. SkyePharma PLC was the topic in 21 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
01/28/16 11:04 AMFTSE turns south as banks, retail provide ballast - Interactive Investor - FTSE turns south as banks, retail provide ballastInteractive Investor... Jimmy Choo (CHOO), Quarto (QRT), Renishaw (RSW), Daily Mail & General Trust (DMGT), Lighthouse (LGT), Redefine Int'l (RDI), NetPlay TV (NPT), Kibo Mining (KIBO), Cpl Resources (CPS), Sanne (SNN), Skyepharma (SKP) and Matchtech (MTEC).and more »
01/11/16 02:33 AMSkyepharma 2015 revenue to be ahead of expectations -
01/11/16 01:33 AMSkyepharma estimates full-year revenue ahead of its expectations -
01/07/16 03:06 PMSkyePharma Plc : Fairly valued, but don’t skip the other factors -
12/15/15 10:33 AMSkyepharma skips on Pacira's Exparel agreement with FDA -
12/10/15 03:31 AMSkyePharma Plc breached its 50 day moving average in a Bullish Manner : December 10, 2015 -
11/26/15 05:53 AMSkyepharma's year-end cash to be above expectations -
11/24/15 09:41 AMSkyePharma Plc – Value Analysis (LONDON:SKP) : November 24, 2015 -
10/08/15 03:16 AMIs Now The Time To Invest In AstraZeneca plc, Indivior plc And Skyepharma plc? -
10/05/15 06:45 AMWhich Offers The Most Potential Profit For Investors: AstraZeneca plc, SkyePharma PLC, Hikma Pharmaceuticals Plc Or Shire PLC? -
09/10/15 03:23 AMWhy SABMiller PLC, Skyepharma PLC, Persimmon plc And Next plc Are Four Of The Hottest Growth Plays In Town! -
08/26/15 05:33 AMCould SkyePharma PLC Outperform Shire PLC And Hikma Pharmaceuticals Plc? -
08/26/15 03:05 AMBUZZ-SkyePharma: strong first-half boosts stock - [Reuters - UK Focus] - ** The specialty pharmaceutical company's shares up 5.8 pct, making them top gainers on the FTSE Small Cap Index , after reporting strong H1 results and indicating a better-than-expected full year ** SkyePharma ...
About SkyePharma PLC

SkyePharma PLC logoSkyepharma PLC (Skyepharma) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company's products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company's products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company's product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals' DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SKP
  • CUSIP:
Key Metrics:
  • Previous Close: $5.84
  • 50 Day Moving Average: $466.0970
  • 200 Day Moving Average: $407.9470
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $19.7500 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha